Navigation Links
Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
Date:12/19/2013

es and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Dec. 19, 2013 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or developme
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen Announces 2014 First Quarter Dividend
2. Amgen To Present At The Oppenheimer 24th Annual Healthcare Conference
3. Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
4. Amgens Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94
5. Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
6. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
7. Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgens Acquisition of Onyx
8. Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
9. Amgen To Participate At Citis 8th Annual Biotech Conference
10. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
11. Amgen to Highlight New Data at Upcoming ESC Congress 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 ... audience, has updated the incredibly successful Serialisation Countdown calendar ... interactive PDF, available at pharmaserialisation.com shows the ... which they will be coming into force. ... longer a matter of "if", but "when" they will ...
(Date:9/18/2014)... 2014  A $3 million grant from The Glenn ... Michigan to establish a national center of excellence in ... Aging Research at U-M will focus on exploiting and ... effects of aging and postpone diseases in animal models. ... help develop medications that may help people live longer, ...
(Date:9/18/2014)... PLAINSBORO, N.J. , Sept. 18, 2014 ... the National Hemophilia Foundation,s (NHF) new three-year initiative, ... to people with hemophilia and their families/caregivers to ... can impede disease management. The curriculum for the ... Your Provider About Pain , focuses on improving ...
Breaking Medicine Technology:Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3
... TARRYTOWN, N.Y., Nov. 2, 2011 Siemens Healthcare Diagnostics ... a partnership aimed at setting new standards in ... of patients, infectious disease states and potential treatment paths. ... make existing Siemens molecular HIV tests compatible with the recently ...
... world leader in diabetes care, announced today that it has ... (DHF), a non-profit organization that raises diabetes awareness and connects ... of the Drive the Switch program, which has motivated more ... and their doctor about options for insulin delivery, like the ...
Cached Medicine Technology:New Siemens - Illumina Partnership Targets Clinical Infectious Disease Testing Using Next-Generation Sequencing 2New Siemens - Illumina Partnership Targets Clinical Infectious Disease Testing Using Next-Generation Sequencing 3Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 2Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 3Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 4Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 5Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 6Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 7
(Date:9/18/2014)... ORLANDO, Fla., and DENVER (PRWEB) September 18, 2014 ... office in Orlando. This new office, managed by Todd ... provide health systems in the southeast with the benefits ... without sacrificing the knowledge and advantage of local project ... regional offices, NexCore has expanded its presence across the ...
(Date:9/18/2014)... September 18, 2014 Once again, Hickman’s ... breakfast restaurants around the Valley to celebrate PJs & ... “World Egg Day”: Friday, October 10, 2014. The “breakfast ... locations to benefit Arizona’s Children Association (AzCA) foster care ... dinner at each participating restaurant on October 10 are ...
(Date:9/18/2014)... are trying to learn more about a condition called ... young athletes. In people with sickle cell trait, ... breakdown that can lead to kidney damage and cardiac ... in the United States collapsed and died during training ... "More student-athletes with sickle cell trait have died ...
(Date:9/18/2014)... decades, researchers have tried to develop broadly effective vaccines ... malaria, and tuberculosis. While limited progress has been made ... available that can protect most people from these devastating ... when vaccines just aren,t working? , At Caltech, Nobel ... problem in a different way. Whereas vaccines introduce substances ...
(Date:9/18/2014)... to support private efforts to provide mental health services ... for similar efforts should federal officials decide to expand ... the VA health system, according to a new RAND ... joint project of philanthropic groups and major academic medical ... and other services to veterans and their families. , ...
Breaking Medicine News(10 mins):Health News:NexCore Group Opens Regional Office in Orlando, Florida 2Health News:October 10th Is 6th Annual PJs & Eggs: Hickman’s Family Farms and Breakfast Restaurants Partner to Benefit Arizona Foster Children 2Health News:Scientists Studying Sickle Cell Trait 2Health News:A new way to prevent the spread of devastating diseases 2Health News:A new way to prevent the spread of devastating diseases 3Health News:A new way to prevent the spread of devastating diseases 4Health News:A new way to prevent the spread of devastating diseases 5Health News:Study provides insight about providing private mental health service to veterans 2Health News:Study provides insight about providing private mental health service to veterans 3
... the U.S., demonstrated both the efficacy and ... with nasal symptoms associated with perennial allergic ... today the U.S. Food and Drug Administration (FDA) ... children aged 2-5,years old for the treatment of ...
... unclear, experts say , , MONDAY, Sept. 22 (HealthDay News) ... to take much longer to get to the hospital when ... new study finds. , The finding suggests that patients without ... critical window for time-sensitive care following a heart attack, the ...
... Cyberonics, Inc. (Nasdaq:,CYBX) today announced that its corporate ... The facility incurred no damage from the ... resulting in the Company operating from its,disaster recovery ... returned to normal, including all shipments and production ...
... experience trouble, study finds , , MONDAY, Sept. 22 (HealthDay ... -- which include Crestor, Lipitor, Pravachol and Zocor -- ... Canadian study indicates. , Delirium is a common, and ... of surgery, according to study lead author Dr. Donald ...
... previously unknown mechanism of immunity suggests that there may ... adults against Streptococcus pneumoniae (pneumococcal) infection, say researchers at ... (HSPH). The findings, published in the open-access journal ... development of novel pneumococcal vaccines. (The current vaccine, Prevnar, ...
... Pa., Sept. 22 A group of southeastern,Pennsylvania ... on,Thursday, September 25 at 12:00 PM at their ... maternity care crisis in Pennsylvania, and how a,legislative ... State,Representative Mike Vereb (R-Montgomery) and other legislators from,southeastern ...
Cached Medicine News:Health News:FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old 2Health News:FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old 3Health News:FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old 4Health News:Heart Attack Care Often Delayed for the Poor 2Health News:Heart Attack Care Often Delayed for the Poor 3Health News:Cyberonics Corporate Headquarters Fully Operational Following Hurricane Ike 2Health News:Cyberonics Corporate Headquarters Fully Operational Following Hurricane Ike 3Health News:Cholesterol Drugs May Raise Post-Op Delirium Risk 2Health News:Cholesterol Drugs May Raise Post-Op Delirium Risk 3Health News:New insights could lead to a better pneumococcal vaccine 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: